UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH<br />
conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in<br />
patients with epithelial ovarian (EOC), fallopian tube, or peritoneal<br />
cancer who are in second or third complete remission.<br />
Authors*: Paul Sabbatini, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nicola M. Spirtos, Carolyn Muller,<br />
Benedict B. Benigno, Matthew A. Powell, Emily Berry, Krishnansu Sujata Tewari, Parviz Hanjani, Wei Deng,<br />
Heather A. Lankes, Carol Aghajanian<br />
Abstract #: 5517<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #340<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5517)<br />
__________________________________________________________________________<br />
Pembrolizumab in advanced endometrial cancer: Preliminary results<br />
from the phase Ib KEYNOTE-028 study.<br />
Authors*: Patrick Alexander Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J. Pishvaian,<br />
Hope S. Rugo, Igor Puzanov, Mark Aloysuis Morgan, Janice M. Mehnert, Kyaw Lwin Aung, Marion Carrigan,<br />
Sanatan Saraf, Mei Chen, Jean-Charles Soria<br />
Abstract #: 5581<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #404<br />
Session: Gynecologic Cancer<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 5581)<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple<br />
clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late<br />
stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC<br />
patients, including with <strong>UCSF</strong>s Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with<br />
large academic medical centers & consortia in order to expand the novel therapies available to patients. She<br />
was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance<br />
& is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative<br />
working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>,<br />
Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends<br />
from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
*<strong>UCSF</strong> authors in bold<br />
79
Change language